Trial · NCT02939937

Effect of Phenytoin on the Ganglion Cell Layer in Patients With Optic Neuritis

NCT02939937, Phase 2, Completed, Tehran University of Medical Sciences; results first posted 2019-08-12

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Effect of Phenytoin on the Ganglion Cell Layer in Patients With Optic Neuritis. Trials, record NCT02939937. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02939937

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Effect of Phenytoin on the Ganglion Cell Layer in Patients With Optic Neuritis
NCT number: NCT02939937
Status: Completed
Phases: Phase 2
Enrollment: 71 participants, actual
Lead sponsor: Tehran University of Medical Sciences
Conditions: Optic Neuritis
Interventions: Phenytoin, placebo
First posted: 2016-10-20
Last updated: 2019-08-12
Results first posted: 2019-08-12
Limitations and caveats: 1. Shorter follow up~2. Poor compliance for oral drug intake

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Retinal Ganglion Cell Inner Plexiform Layer Thickness	Measured at baseline and month 1, 6	ganglion cell inner plexiform layer thickness measure in 8 sectors by Heidelberg spectral-domain Optical Coherence Tomography
Primary	Macular Layer Thickness	Measured at baseline and month 1, 6	macular layer thickness measure in 8 sectors by Heidelberg spectral domain Optical Coherence Tomography
Primary	Best Corrected Visual Acuity	at baseline and month 6	Best corrected visual acuity is converted to logMAR (logarithms of minimum angle of resolution) by statistical calculation.
Primary	Visual Field Mean Deviation in Decibel	Measured at baseline and month 6	The visual field is performed by the Swedish interactive thresholding algorithm standard 24-2 perimeter (Carl Zeiss mediated, Dublin, California).
Secondary	Retinal Nerve Fibre Layer Thickness in Micrometer	Measured at baseline and month1 ,6	Retinal nerve fibre layer thickness measure in 8 sectors by Heidelberg spectral-domain Optical Coherence Tomography

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Retinal Ganglion Cell Inner Plexiform Layer Thickness	Measured at baseline and month 1, 6	incomplete follow up from baseline to 6 month	micron	MEAN
PRIMARY	Macular Layer Thickness	Measured at baseline and month 1, 6	incomplete follow up	micron	MEAN
PRIMARY	Best Corrected Visual Acuity	at baseline and month 6	incomplete follow up	log mar	MEAN
PRIMARY	Visual Field Mean Deviation in Decibel	Measured at baseline and month 6	incomplete follow up	db	MEAN
SECONDARY	Retinal Nerve Fibre Layer Thickness in Micrometer	Measured at baseline and month1 ,6	incomplete follow up	micron	MEAN

Source ClinicalTrials.gov

Results by group26

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Retinal Ganglion Cell Inner Plexiform Layer Thickness	Phenytoin	baseline	36.56	Standard Deviation 6.61	micron
Retinal Ganglion Cell Inner Plexiform Layer Thickness	Placebo	baseline	34.65	Standard Deviation 8.49	micron
Retinal Ganglion Cell Inner Plexiform Layer Thickness	Phenytoin	1 month	31	Standard Deviation 6.61	micron
Retinal Ganglion Cell Inner Plexiform Layer Thickness	Placebo	1 month	29.42	Standard Deviation 5.98	micron
Retinal Ganglion Cell Inner Plexiform Layer Thickness	Phenytoin	6 months	30.70	Standard Deviation 5.56	micron
Retinal Ganglion Cell Inner Plexiform Layer Thickness	Placebo	6 months	32.12	Standard Deviation 9.10	micron
Macular Layer Thickness	Phenytoin	baseline	262.73	Standard Deviation 22.02	micron
Macular Layer Thickness	Placebo	baseline	265.98	Standard Deviation 22.5	micron
Macular Layer Thickness	Phenytoin	1 month	255	Standard Deviation 19.72	micron
Macular Layer Thickness	Placebo	1 month	264.39	Standard Deviation 22.53	micron

1 to 10 of 26Source ClinicalTrials.gov

See all 26 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Phenytoin	21
Overall Study	STARTED	Placebo	50
Overall Study	COMPLETED	Phenytoin	15
Overall Study	COMPLETED	Placebo	47
Overall Study	NOT COMPLETED	Phenytoin	6
Overall Study	NOT COMPLETED	Placebo	3

Source ClinicalTrials.gov

Adverse events4

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	skin reaction	Skin and subcutaneous tissue disorders	Phenytoin	4	21	4
other	skin reaction	Skin and subcutaneous tissue disorders	Placebo	0	50	0
serious	steven johnson	Skin and subcutaneous tissue disorders	Phenytoin	1	21	1
serious	steven johnson	Skin and subcutaneous tissue disorders	Placebo	0	50	0

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Phenytoin	0	21
Total, all-cause mortality	Placebo	0	50
Total, other adverse events	Phenytoin	4	21
Total, other adverse events	Placebo	0	50
Total, serious adverse events	Phenytoin	1	21
Total, serious adverse events	Placebo	0	50

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Phenytoin vs Placebo: deaths from any cause	Trial comparisons
Phenytoin vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02939937

GET https://conductscience.org/api/trials/v1/NCT02939937/results?page=2

API reference For AI assistants